EDAP TMS (EDAP) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
EDAP TMS SA, a leading company in robotic energy-based therapies, has announced interim results from a Phase 3 study on robotic High-Intensity Focused Ultrasound (HIFU) for treating deep infiltrating endometriosis. Although the primary endpoint of reduced acute pelvic pain was not met, significant improvements were observed in endometriosis and digestive symptoms, and the safety profile was confirmed as excellent. The study continues with patients from the Sham treatment arm now opting for HIFU therapy, indicating ongoing confidence in the potential benefits of the treatment.
For further insights into EDAP stock, check out TipRanks’ Stock Analysis page.
